Cargando…

Case report: Gemcitabine intravesical hyperthermic infusion combined with tislelizumab in muscle invasive bladder urothelium carcinoma

BACKGROUND: Muscle invasive bladder urothelium carcinoma is a common urinary tract tumor. With the deepening of research, more and more treatment methods are applied in clinical practice, extending the life of patients. Among them, the clinical application of chemotherapeutic intravesical hypertherm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Du, Zheng, Yin, Huaqi, Zhao, Shiming, Ma, Yongkang, Sun, Zhenghui, Dong, Bingqi, Zhu, Mingkai, Zhu, Chaoshuai, Peng, Jiangshan, Yang, Tiejun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816863/ https://www.ncbi.nlm.nih.gov/pubmed/36620538 http://dx.doi.org/10.3389/fonc.2022.1062655

Ejemplares similares

Clinical study of renal artery cold perfusion combined with laparoscopic nephron retention in the treatment of complex renal angiomyolipoma
por: Zhu, ChaoShuai, et al.
Publicado: (2023)

The significance of transrectal ultrasound and urologist_dually guided pelvic floor muscle exercise in improving urinary continence after radical prostatectomy
por: Huaqi, Yin, et al.
Publicado: (2023)

Correction: The significance of transrectal ultrasound and urologist_dually guided pelvic floor muscle exercise in improving urinary continence after radical prostatectomy
por: Huaqi, Yin, et al.
Publicado: (2023)

A laparoscopic radical inguinal lymphadenectomy approach partly preserving great saphenous vein branches can benefit for patients with penile carcinoma
por: Ma, Yongkang, et al.
Publicado: (2022)

Hyperthermia inhibits cellular function and induces immunogenic cell death in renal cell carcinoma
por: Huaqi, Yin, et al.
Publicado: (2023)

PD-1 inhibitor toripalimab with gemcitabine as a neoadjuvant therapy for muscle-invasive bladder urothelial carcinoma: A case report
por: Yin, Huaqi, et al.
Publicado: (2022)

BCG Induced Necrosis of the Entire Bladder Urothelium
por: Krönig, Malte, et al.
Publicado: (2015)

Intravesical Gemcitabine versus Intravesical Bacillus Calmette–Guérin for the Treatment of Non-Muscle Invasive Bladder Cancer: An Evaluation of Efficacy and Toxicity
por: Prasanna, Thiru, et al.
Publicado: (2017)

Identification of a Prognostic Signature Associated With the Homeobox Gene Family for Bladder Cancer
por: Dong, Bingqi, et al.
Publicado: (2021)

Tumor Expression Profile Analysis Developed and Validated a Prognostic Model Based on Immune-Related Genes in Bladder Cancer
por: Dong, Bingqi, et al.
Publicado: (2021)

Changes in the Ultrastructure of the Bladder Urothelium in Patients with Interstitial Cystitis after Intravesical Injections of Platelet-Rich Plasma
por: Lee, Yu-Khun, et al.
Publicado: (2022)

Clinical significance of circulating tumour cells and Ki-67 in renal cell carcinoma
por: Song, Jinbo, et al.
Publicado: (2021)

TERT C228T mutation in non‐malignant bladder urothelium is associated with intravesical recurrence for patients with non‐muscle invasive bladder cancer
por: Hayashi, Yujiro, et al.
Publicado: (2020)

Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients
por: de Jong, Joep J., et al.
Publicado: (2018)

A scalable hyperthermic intravesical chemotherapy (HIVEC) setup for rat models of bladder cancer
por: Van Hattum, J. W., et al.
Publicado: (2022)

Adjuvant Hyperthermic Intravesical Chemotherapy in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer
por: Magalhães, Joana C, et al.
Publicado: (2023)

Intravesical gemcitabine for non-muscle invasive bladder cancer: An abridged Cochrane Review
por: Han, Mi Ah, et al.
Publicado: (2021)

Bladder preservation in complicated invasive urothelial carcinoma following treatment with cisplatin/gemcitabine plus tislelizumab: A case report
por: Yang, Rui, et al.
Publicado: (2023)

Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiotherapy as the induction therapy for patients with locally advanced and borderline resectable pancreatic cancer
por: Lu, Changchang, et al.
Publicado: (2022)

Current Researches on Nanodrug Delivery Systems in Bladder Cancer Intravesical Chemotherapy
por: Lu, Yilei, et al.
Publicado: (2022)

PD-L2 Is Constitutively Expressed in Normal and Malignant Urothelium
por: Dowell, Alexander C., et al.
Publicado: (2021)

Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases
por: Li, Teng, et al.
Publicado: (2023)

Severe thyrotoxicosis induced by tislelizumab: a case report and literature review
por: Huo, Liman, et al.
Publicado: (2023)

The Response of Variant Histology Bladder Cancer to Intravesical Immunotherapy Compared to Conventional Cancer
por: Gofrit, Ofer N., et al.
Publicado: (2016)

Intravesical ALT-803 for BCG-unresponsive Bladder Cancer – A Case Report
por: Huang, Jeffrey, et al.
Publicado: (2017)

Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer
por: Steinberg, Ryan L., et al.
Publicado: (2015)

Hyperthermic intravesical chemotherapy with mitomycin‐C for the treatment of high‐risk non‐muscle‐invasive bladder cancer patients
por: Conroy, Samantha, et al.
Publicado: (2022)

Complete remission in a patient with metastatic gastric cancer receiving tislelizumab combined with chemotherapy: a case report
por: Zhu, Zhe, et al.
Publicado: (2023)

The Efficacy of Intra-Arterial Plus Intravesical Chemotherapy Versus Intravesical Chemotherapy Alone After Bladder-Sparing Surgery in High-Risk Bladder Cancer: A Systematic Review and Meta-Analysis of Comparative Study
por: Zhou, Zhongbao, et al.
Publicado: (2021)

Case Report: Transarterial Chemoembolization in Combination With Tislelizumab Downstages Unresectable Hepatocellular Carcinoma Followed by Radical Salvage Resection
por: Chao, Jiashuo, et al.
Publicado: (2021)

Thermal Intravesical Chemotherapy Reduce Recurrence Rate for Non-muscle Invasive Bladder Cancer Patients: A Meta-Analysis
por: Liu, Kang, et al.
Publicado: (2020)

Biopsies of the normal-appearing urothelium in primary bladder cancer
por: Librenjak, Davor, et al.
Publicado: (2010)

A multi-institutional retrospective study of hyperthermic plus intravesical chemotherapy versus intravesical chemotherapy treatment alone in intermediate and high risk nonmuscle-invasive bladder cancer
por: Ruan, Qiang, et al.
Publicado: (2021)

Oncological Outcomes of Sequential Intravesical Gemcitabine and Docetaxel in Patients with Non-Muscle Invasive Bladder Cancer
por: Milbar, Niv, et al.
Publicado: (2017)

Bladder Contracture – A Rare and Serious Side Effect of Intravesical Bacillus Calmette-Guérin Therapy
por: Garcia, Cindy, et al.
Publicado: (2015)

Neoadjuvant systemic and intravesical chemotherapy with partial cystectomy for muscle invasive bladder cancer with concomitant CIS
por: Plambeck, Benjamin D., et al.
Publicado: (2023)

The different predictive value of mean platelet volume-to-lymphocyte ratio for postoperative recurrence between non-muscular invasive bladder cancer patients treated with intravesical chemotherapy and intravesical chemohyperthermia
por: Wang, Chengbo, et al.
Publicado: (2023)

Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial
por: Ding, Kaiyang, et al.
Publicado: (2023)

Tislelizumab in combination with gemcitabine plus cisplatin chemotherapy as first-line adjuvant treatment for locally advanced or metastatic bladder cancer: a retrospective study
por: Ren, Xiang, et al.
Publicado: (2022)

Systemic Sequential Therapy of CisGem, Tislelizumab, and Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma Conversion Therapy
por: Ding, Yuan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_uqfs5jfriuqfg8e9iehejv7805